Randomised studies have shown that switching to a TAF-based regimen is generally safer than continuing to take TDF-containing regimens, particularly for bone and kidney health • How these trial results might have impacted on daily prescriptions in clinical practice is unknown and there is little data describing the population who have been switched to TAF-based regimens
Use of TAF with a HIV-RNA <50 cp/mL in clinical practice.
G. Nunnari;G. F. Pellicanò.
2018-01-01
Abstract
Randomised studies have shown that switching to a TAF-based regimen is generally safer than continuing to take TDF-containing regimens, particularly for bone and kidney health • How these trial results might have impacted on daily prescriptions in clinical practice is unknown and there is little data describing the population who have been switched to TAF-based regimensFile in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
